GlassScriptPhysician profile
Bethany B Davis
NPI 1881763001
$7,881.65
in general payments reported to CMS, 2019-2025
28 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $16.76 · 2021: $53.09 · 2023: $3,959 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,372 · Consulting Fee: $1,800 · Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,372.30 |
| Consulting Fee | $1,800.00 |
| Food and Beverage | $1,240.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $2,231.68 | 2025 | |
| Neurocrine Biosciences, INC. | $2,040.02 | 2023 | |
| Abbvie INC. | $1,800.00 | 2023 | Vraylar |
| Avanir Pharmaceuticals, INC. | $1,303.59 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $195.39 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.32 | 2023-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $80.45 | 2019 | |
| Lundbeck LLC | $52.53 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $17.32 | 2021 | |
| Stryker Corporation | $16.42 | 2023 | Prevalon |
| Takeda Pharmaceuticals U.S.A., INC. | $14.93 | 2019 |
17 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.